Study of the anti-tumor effects by oligonucleotides among the patients with primary lung cancer

Study of the anti-tumor effects by oligonucleotides among the patients with primary lung cancer - Study of the anti-tumor effects by oligonucleotides among the patients with primary lung cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017816

Enrollment

Registered

2015-06-04

Start date

2012-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Oligonucleotides

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosed with primary lung cancer 2. Estimated life expectancy at least three months 3. With written informed consent

Exclusion criteria

Exclusion criteria: 1. Having any treatment for active local or systemic infectious disease 2. Any multiple cancer 3. Needs treatment with systemic corticosteroids or immunosuppressive agents 4. Problematic mental disorder 5. Investigator considers to be inappropriate to participate in this study.

Design outcomes

Primary

Measure	Time frame
T cell proliferation assay	—

Secondary

Measure	Time frame
Inflammatory cytokines	—

Countries

Japan

Contacts

Public ContactNobuaki Kobayashi

Yokohama City University Department of Respiratory Medicine

nkobayas@yokohama-cu.ac.jp045-787-2630

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026